Class / Patent application number | Description | Number of patent applications / Date published |
514210600 | 9 to 11 amino acid residues in the peptide chain | 25 |
20110009344 | Control of radiation injury - The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with said peptide at 72 hours after WBI and, testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of said peptide at 72 hours after WBI and wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals. | 01-13-2011 |
20110015139 | HISTIDINE RELATED COMPOUNDS FOR IDENTIFYING AND BLOCKING AMYLOID BETA ION CHANNELS - The present disclosure relates to amyloid beta (Aβ) channels and the diseases and disorders caused by abnormal activity in these channels, such as Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy. The disclosure provides compositions and methods that block AO channel activity and/or reduce Aβ-induced toxicity in a cell. Compositions comprised of compounds having histidine coordinating capacity are used in methods to prevent, reduce, or eliminate damage caused by Aβ ion channels. | 01-20-2011 |
20110071092 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF - The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. | 03-24-2011 |
20110144037 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use - The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α | 06-16-2011 |
20110166083 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN - The use is claimed of opioid peptides with a novel structure, which in addition to the pharmacophore contain structural elements that interact with neurotensisn receptors. Due to the synergistic interaction with the additional element, an augmented analgesic activity is obtained, capable of being used for an extended period due to decreased drug tolerance induction. These compounds may be of particular use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatoid, gout, neurodegeneration, post-operative or post-accidental lesions, or oncogenic lesions. | 07-07-2011 |
20110166084 | Controlled release composition and method of producing the same - A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. | 07-07-2011 |
20110212902 | METAL-BINDING COMPOUNDS AND USES THEREFOR - The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention. | 09-01-2011 |
20110212903 | METAL-BINDING COMPOUNDS AND USES THEREFOR - The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention. | 09-01-2011 |
20110251140 | PEPTIDE ANTAGONIST OF INTERLEUKIN-15 ACTIVITY - The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor α (TNFα) induction and the expression of IL-8 and IL-6 by the IL-15 receptor a subunit (IL-15Rα), all these effects mediated by the binding of the peptide to the IL-15Rα. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15Rα is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer. | 10-13-2011 |
20110257105 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF - The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 10-20-2011 |
20120309696 | ACTH ANTAGONIST PEPTIDES - The present invention provides methods of treating overproduction of cortisol in a subject by administering to the subject a peptide that antagonizes adrenocorticotropin hormone (ACTH) to block the activation of melanocortin 2 receptors. | 12-06-2012 |
20130096073 | Casein Derived Peptides And Uses Thereof - Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors. | 04-18-2013 |
20130143824 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 06-06-2013 |
20130190255 | NOVEL BIOLOGICALLY ACTIVE PEPTIDES AND THEIR NEW USES - Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual. | 07-25-2013 |
20130303464 | STABLE READY-TO-USE CETRORELIX INJECTION - The present invention discloses a stable ready-to-use aqueous pharmaceutical preparation containing Cetrorelix or its pharmaceutically acceptable salt, wherein the preparation does not contain any surfactant. Further, the present invention discloses process for the preparation of said stable ready-to-use aqueous pharmaceutical preparation. | 11-14-2013 |
20140128330 | METHOD OF DIAGNOSIS AND PROGNOSIS - A method of measuring Gadd45β expression comprising the step of measuring Gadd45β expression levels in a sample of cells, for example CD 138 expressing cells, obtained from a subject known to have or suspected of having a haematological malignancy. Expression levels may be used in diagnosis, for example of multiple myeloma, in providing a prognosis, for example in a patient having multiple myeloma or in guiding selection of an appropriate treatment agent, especially a treatment agent comprising Gadd45β and or MKK7 inhibitors. Also datasets comprising measured expression levels from multiple subjects. | 05-08-2014 |
20140288011 | GENETIC ASSOCIATION - This invention is directed in part to methods, assays and/or kits for identifying an individual who has an autoimmune disease (such as rheumatoid arthritis), or who has an altered risk for having or developing the autoimmune disease. The methods in one aspect comprise determining the presence or absence of a nucleic acid variant within the somatostatin receptor type 2 (sstr2) gene in the individual's nucleic acids, wherein the presence of the nucleic acid variant is correlated with having the autoimmune disease or the altered risk. The nucleic acid variant may, for example, be a single nucleotide polymorphism (SNP). | 09-25-2014 |
20140296164 | Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand - The present invention describes peptide drugs that inhibit the interaction between CAL and CFTR, and other proteins in cystic fibrosis and other diseases. These invented drugs have been chemically optimized to impart solubility, stability, cell permeability, mucus penetration, intracellular targeting and sequestration, increased potency and non-immunogenicity, while conserving and imparting efficacy. This renders these compositions suitable for human use, which is exemplified by use in the treatment of cystic fibrosis. | 10-02-2014 |
20150038435 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF - The present invention is related to N-terminally fatty acid modified peptides or oligopeptides and pharmaceutical compositions comprising such. | 02-05-2015 |
20150065436 | INHIBITING INTERACTION BETWEEN HIF-1ALPHA AND p300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES - The present invention relates to peptidomimetics that mimic helix αB of the C-terminal transactivation domain of HIF-1α. Methods of using the peptidomimetics to, e.g., inhibit the HIF-1α-p300/CBP interaction, are also disclosed. | 03-05-2015 |
20150080322 | SUSTAINED-RELEASE COMPOSITION AND METHOD FOR PRODUCING THE SAME - Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same. | 03-19-2015 |
20150133393 | Novel JNK Inhibitor Molecules for Treatment of Various Diseases - The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy. | 05-14-2015 |
20150307487 | SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES - The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG)exp, that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium, binds the 5′C | 10-29-2015 |
20150359840 | Autophagy-Inducing Peptide Analogs - An autophagy-inducing compound comprises an autophagy-inducing peptide comprising Beclin 1 peptides immediately N- and C-terminally flanked by moieties R | 12-17-2015 |
20160115200 | New Use for JNK Inhibitor Molecules for Treatment of Various Diseases - The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy. | 04-28-2016 |